Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20804532 | 0.88 | MAOB (0.59) | MAOBMAOAAPPNR4A2PARP10 | |
| SCHEMBL21944603 | 0.84 | MAOB (0.53) | MAOBMAOAAPPNR4A2PARP10 | |
| SCHEMBL29142397 | 0.83 | CYP1A2 (0.58) | MAOBNR4A2 | |
| SCHEMBL22597082 | 0.82 | MAOB (0.47) | MAOBMAOAAPPNR4A2PARP10 | |
| SCHEMBL21477287 | 0.82 | MAOB (0.60) | MAOBMAOAAPPNR4A2PARP10 | |
| SCHEMBL22597338 | 0.80 | MAOB (0.69) | MAOBMAOAAPPNR4A2 | |
| SCHEMBL20804354 | 0.80 | MAOB (0.67) | MAOBMAOAAPPNR4A2PARP10 | |
| SCHEMBL18002896 | 0.78 | MAOB (0.65) | MAOBMAOAAPPNR4A2 | |
| SCHEMBL21945065 | 0.77 | CYP4F2 (0.41) | MAOB | |
| SCHEMBL13321691 | 0.76 | MAOB (0.60) | MAOBMAOAAPPNR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961231-B2 | NTCP inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-03-30 | — | — | US | disclosed |
| US-20210040072-A1 | NTCP Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-02-11 | — | — | US | disclosed |
| WO-2020215267-A1 | USE OF NTCP INHIBITORS IN PREVENTING AND TREATING HEPATOCARCINOGENESIS | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2020-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040072-A1 | NTCP Inhibitors | HAVCR2, NPC1, HMGCR | MAOB 4651/4885MAOA 4465/4885APP 589/4885 |
| US-10961231-B2 | NTCP inhibitors | HAVCR2, NPC1, HMGCR | MAOB 4651/4885MAOA 4465/4885APP 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.